

Press Release



Announcement of the Establishment of International Representative Office in London

TOKYO, April 1st, 2021 - ASKA Pharmaceutical Co., Ltd. (Headquarters: Minato-ku, Tokyo, President: Takashi Yamaguchi, hereinafter “ASKA or Company”), a wholly owned subsidiary of ASKA Pharmaceutical Holdings Co., Ltd. announced that ASKA has established an international representative office in London (hereinafter “IRO”), England, UK on April 1st, 2021.

The Company intends to utilize the IRO primarily as a physical base of operations for business development activities in Europe, to both consolidate our collaborations with existing partners and accelerate activities with overseas pharmaceutical/biotech companies and academic institutes for new alliances.

ASKA concentrates its management resources on the three priority therapeutic areas of internal medicine, obstetrics and gynecology, as well as urology. The Company aims to become “a Total Healthcare Company with a Strong Foundation as a Specialty Pharma Company” by actively promoting drug discovery and development with an increasing international activity to compete in the current environment more effectively.

With the establishment of the IRO in London, the previous Frankfurt International Representative Office has been closed.

【Contact】

Corporate Planning Department, ASKA Pharmaceutical Holdings Co., Ltd.
TEL: +81-3-5484-8366